2 recruiting, 1 active not recruiting, 1 completed, 1 withdrawn. 4 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow JNJ-75276617: new trials by email Literature Review of JNJ-75276617 trials Research Report on JNJ-75276617
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias JNJ-75276617, Fludarabine, Cytarabine - Acute Leukemias, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2025-12-26 | 2025-06-22 | |
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia 14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias | Phase 1 | Completed | Janssen Research & Development, LLC | 6 | 2025-11-18 | 2026-09-25 |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Bleximenib, Venetoclax (VEN), Azacitidine (AZA) - Leukemia, Myeloid, Acute | Phase 3 | Recruiting | Janssen Research & Development, LLC | 600 | 2025-06-04 | 2026-11-03 |
| A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Bleximenib, Venetoclax (VEN), Azacitidine (AZA) - Leukemia, Myeloid, Acute | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 196 | 2022-10-04 | 2026-09-25 |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) Bleximenib - Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 420 | 2021-05-19 | 2026-11-04 |
Leukemia, Myeloid, Acute (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Biphenotypic, Acute (1)
Janssen Research & Development, LLC (5)
United Kingdom (4) · Australia (3) · Canada (3) · France (3) · Spain (3) · United States (3) · Belgium (2) · Brazil (2) · China (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · South Korea (2) · Taiwan (2)
2023 (2)